7.4.4.3.1  Summary of evidence and recommendations for targeted therapy in papillary metastatic RCC,
Summary of evidence,LE
Cabozantinib improved PFS over sunitinib in patients with advanced pRCC without additional   molecular testing.,2a
Savolitinib improved PFS over sunitinib in patients with MET-driven advanced pRCC.,2a
Pembrolizumab resulted in long-term median OS in a single-arm study in the pRCC subgroup.,2a
